Genmab — Februar 2020
-
grund til
-
GEN1046
-
DuoBody-PD-L1x4-1BB, one of the products that we are developing along with BioNTech, has the potential to be first-in-class and to provide Genmab with a truly differentiated PD-L1 products. There is a high unmet medical need to improve on checkpoint blockers, and we have seen strong pre-clinical data and encouraging early signs of activity in patients who failed PD-1 and/or PD-L1 checkpoint blockers for DuoBody-PD-L1x4-1BB.
-
God morgen.
-
Live Corona update: https://www.worldometers.info/coronavirus/
-
God morgen.
-
U.S. FDA Filing Acceptance and Priority Review for sBLA, Submitted by Novartis, for Ofatumumab in Relapsing Multiple Sclerosis
-
Novartis anticipates potential regulatory approval in the U.S. in June 2020
-
Marketing Authorization Application for ofatumumab in RMS also accepted for review by EMA with potential regulatory approval anticipated by Novartis by the second quarter of 2021
-
Gode nyheder Jeps.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind